GlaxoSmithKline (GSK.N) CEO: The company is in very constructive communication with the U.S. government regarding drug pricing, but declined to comment on specific details.
2025-10-29
GlaxoSmithKline (GSK.N) CEO: The company is in very constructive communication with the U.S. government regarding drug pricing, but declined to comment on specific details.